MRK Jun 2025 75.000 put
| Previous close | 1.1000 |
| Open | 1.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 75.00 |
| Expiry date | 2025-06-20 |
| Day's range | 1.1000 - 1.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 462 |
- Yahoo Finance Video
Alphabet, Microsoft, Southwest earnings: What to watch
Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- Reuters
UPDATE 1-Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda. The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.
ReutersMerck raises 2024 profit forecast on strong sales of cancer drug Keytruda
(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company's shares up more than 2% before the bell. Keytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward the end of the decade. The drug is seeing growth from use for additional types of cancers as well as higher patient demand, Chief Financial Officer Caroline Litchfield said.
